Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2025ChemistrySelect

Design, Synthesis, and Molecular Docking Studies of Triazolylpyridine and Triazolylpyridinylbenzofuran Hybrids as Potential EGFR Inhibitors

View Full Paper
Ask AI
Bookmark
Share

Authors

DEDhanasekar ElumalaiDKD. KathirvelanSLSaraswathi Leelakrishnan

Discussion

Loading...

Member takes

Overview

This research identifies novel triazolylpyridine hybrids as potential EGFR inhibitors, suggesting significant therapeutic potential.

Key Points

  • The synthesized triazolylpyridine hybrids showed stronger binding affinity to EGFR than Gefitinib.
  • Molecular docking revealed that these compounds could effectively inhibit the epidermal growth factor receptor.
  • The synthesis involved a one-pot method using In(OTf)3, indicating an efficient catalytic route.
  • These findings point to the potential of these compounds in targeted anticancer therapy.

Cite This Study

Elumalai et al. (2025) studied this question.

synapsesocial.com/papers/68c238d2b210217d6477964ehttps://doi.org/10.1002/slct.202501972
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Synthesis of Pyrido[2,3‐d]Azolopyrimidinones: Design and Epidermal Growth Factor Receptor‐Targeted Molecular Docking Toward Novel Anticancer Leads2025
  2. 2Advancing EGFR-targeted anticancer strategies: the potential of thiazole, pyrazole, and thiazole–pyrazole hybrids2025
  3. 3Chiral 1,3,5‐Triazines as Potential EGFR Inhibitors: Pharmacophore Modeling, Synthesis, Molecular Docking, Molecular Dynamics Simulation, and Anticancer Evaluation2025
  4. 4Synthesis and in-vitro anti-EGFR screening of new 1,2,3-triazole-benzimidazole hybrids and insilico studies2025
  5. 5Design, Synthesis, <i>In-Silico</i> Study of Novel Benzofuran Thiazolyl Hydrazones as Anticancer Agents Targeting EGFR Kinase2025